You just read:

Despite An Increase in Psoriatic Arthritis Patients Initiated on Cosentyx Over the Past Three Months, the User Base for Novartis' IL-17 Inhibitor Has Remained Stable

News provided by

Spherix Global Insights

Nov 02, 2016, 05:00 ET